Korean J Med.
2010 Apr;78(4):503-506.
A case of thyrotoxicosis after sunitinib treatment
- Affiliations
-
- 1Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea. kgpark@dsmc.or.kr
Abstract
- Sunitinib is a tyrosine-kinase inhibitor used to treat metastatic renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumors. Hypothyroidism is a common side effect of sunitinib therapy. Nevertheless, overt thyrotoxicosis induced by destructive thyroiditis after sunitinib treatment is very rare. Here, we report a patient with overt thyrotoxicosis related to sunitinib therapy.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The clinical characteristics of hypothyroidism after sunitinib treatment in a Korean population
- A Case of Sunitinib-Induced Destructive Thyroiditis
- Intolerance to Sunitinib Treatment in Hemodialysis Patients With Metastatic Renal Cell Carcinoma
- Hypoglycemic Coma in a Patient with Metastatic Renal Cell Carcinoma Treated with Sunitinib
- Sunitinib-induced hypothyroidism
